JP2016515519A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515519A5
JP2016515519A5 JP2016503056A JP2016503056A JP2016515519A5 JP 2016515519 A5 JP2016515519 A5 JP 2016515519A5 JP 2016503056 A JP2016503056 A JP 2016503056A JP 2016503056 A JP2016503056 A JP 2016503056A JP 2016515519 A5 JP2016515519 A5 JP 2016515519A5
Authority
JP
Japan
Prior art keywords
antibody
seq
composition
identified
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515519A (ja
JP6482525B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029308 external-priority patent/WO2014144763A2/en
Publication of JP2016515519A publication Critical patent/JP2016515519A/ja
Publication of JP2016515519A5 publication Critical patent/JP2016515519A5/ja
Application granted granted Critical
Publication of JP6482525B2 publication Critical patent/JP6482525B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503056A 2013-03-15 2014-03-14 高親和性抗gd2抗体 Active JP6482525B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361801287P 2013-03-15 2013-03-15
US61/801,287 2013-03-15
PCT/US2014/029308 WO2014144763A2 (en) 2013-03-15 2014-03-14 High affinity anti-gd2 antibodies

Publications (3)

Publication Number Publication Date
JP2016515519A JP2016515519A (ja) 2016-05-30
JP2016515519A5 true JP2016515519A5 (enExample) 2017-04-13
JP6482525B2 JP6482525B2 (ja) 2019-03-13

Family

ID=51538371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503056A Active JP6482525B2 (ja) 2013-03-15 2014-03-14 高親和性抗gd2抗体

Country Status (9)

Country Link
US (1) US10167341B2 (enExample)
EP (1) EP2968545B1 (enExample)
JP (1) JP6482525B2 (enExample)
KR (1) KR102207859B1 (enExample)
CN (1) CN105705165B (enExample)
AU (1) AU2014228772B2 (enExample)
CA (1) CA2903576C (enExample)
RU (1) RU2680267C2 (enExample)
WO (1) WO2014144763A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2961381T3 (es) 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
EP3256164B1 (en) * 2015-02-09 2020-03-25 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
KR20170034132A (ko) 2015-09-18 2017-03-28 현대자동차주식회사 람다 센서의 피독 제거 장치 및 방법
EP3269739A1 (en) * 2016-07-15 2018-01-17 OGD2 Pharma Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
CA3054081A1 (en) * 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding gd2, nkg2d and cd16
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
CN111373261B (zh) * 2017-11-20 2024-06-14 尤利乌斯·马克西米利安维尔茨堡大学 Cd19 cart细胞可清除表达极低水平cd19的骨髓瘤细胞
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Cd33、nkg2d、及びcd16に結合する多重特異性結合タンパク質、ならびにその使用方法
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
WO2020041565A1 (en) * 2018-08-22 2020-02-27 Memorial Sloan-Kettering Cancer Center Methods for treating neuroblastoma with combination therapy
RU2708136C1 (ru) * 2019-04-15 2019-12-04 Общество с ограниченной ответственностью "Реал Таргет" Новые белковые конструкции для диагностики и терапии gd2-позитивных заболеваний
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
WO2020236562A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
US20220411535A1 (en) * 2019-11-26 2022-12-29 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
WO2022203552A1 (en) * 2021-03-24 2022-09-29 Joint Stock Company "Biocad" Monoclonal antibody that specifically binds to gd2
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CN114456270B (zh) * 2022-03-02 2023-12-22 北京美康基免生物科技有限公司 一种gd2嵌合抗原受体及其应用
JP2025525035A (ja) * 2022-07-25 2025-08-01 バイロネクシス バイオセラピューティクス インコーポレイテッド アデノ随伴ウイルスベクターならびに転移のリスク低減、処置、および予防のためのそれらの使用方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
WO1992018629A1 (en) 1991-04-19 1992-10-29 Genetics Institute, Inc. Recombinant 3f8-type antibodies
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH06105020B2 (ja) 1992-06-09 1994-12-21 ホッペ・アーゲー ラッチ及びロックアップシステム
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
DE69322789T2 (de) 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. Trockenpulverinhalator
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DE69414369T2 (de) 1993-01-19 1999-05-27 Glaxo Group Ltd., Greenford, Middlesex Aerosol-spender und verfahren zu seiner herstellung
EP1978095A1 (en) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2183268C (en) 1994-03-07 2001-05-15 Edward D. Ball Bispecific molecules having clinical utilities
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5886793A (en) 1995-04-04 1999-03-23 Oki Data Corporation Facsimile machine adapted to reduce risk of data loss
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
NZ324374A (en) 1996-01-03 1999-06-29 Glaxo Group Ltd Inhalation device
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE210682T1 (de) 1996-09-03 2001-12-15 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955186A (en) 1996-10-15 1999-09-21 Kennametal Inc. Coated cutting insert with A C porosity substrate having non-stratified surface binder enrichment
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
DE69840723D1 (de) 1997-02-11 2009-05-20 Immunomedics Inc Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
AU750767B2 (en) 1998-01-23 2002-07-25 Immunex Corporation ACPL DNA and polypeptides
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
CA2347734A1 (en) 1998-12-15 2000-06-22 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1461428B1 (en) 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
CA2538719A1 (en) 2002-09-20 2004-04-01 Mcgill University Gd2 ligands
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
US20040220084A1 (en) 2003-05-02 2004-11-04 Jasbir Sandhu Methods for nucleic acid delivery
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
FR2906808B1 (fr) 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-il-12/il-23 항체
ES2961381T3 (es) 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
CN105530959B (zh) * 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Similar Documents

Publication Publication Date Title
US12403180B2 (en) Interleukin-18 variants and methods of use
JP7420866B2 (ja) 核酸ポリペプチド組成物とその使用
JP7581252B2 (ja) Unaアミダイトおよびその使用
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
JP7592034B2 (ja) 核酸ポリペプチド組成物およびその使用
JP7126941B2 (ja) がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
JP2024001021A (ja) 核酸ポリペプチド組成物およびその使用
RU2015143208A (ru) Высокоаффинные антитела kgd2
TWI596116B (zh) 包含專一性辨識cd38之抗體及硼替佐米(bortezomib)之抗腫瘤組合
JP2019107018A5 (enExample)
US20240374679A1 (en) Interleukin-18 mimics and methods of use
JP2024527606A5 (enExample)
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
CN116077647A (zh) 喹啉衍生物与抗体的药物组合
CN105873607A (zh) 能够结合cd123和cd3的双特异性单价双抗体及其用途
JP2015534577A5 (enExample)
JP2013135695A5 (enExample)
TW202108181A (zh) 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物
JP2010535713A5 (enExample)
JP2022501074A5 (enExample)
JP2016502504A5 (enExample)
KR20220035910A (ko) Car-t 세포의 인시츄 모집, 재프로그래밍 및 방출
CN112654346A (zh) 生物分子包覆颗粒和薄膜及其用途
JP6640181B2 (ja) 二重特異性抗原結合ポリペプチド
RU2015119159A (ru) Антитела к интерлейкину 6 и их применение